OPKO Health (NASDAQ:OPK) Stock Passes Below 50 Day Moving Average – What’s Next?

OPKO Health, Inc. (NASDAQ:OPK) shares crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.32 and traded as low as $1.31. OPKO Health shares last traded at $1.32, with a volume of 964,403 shares.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Jefferies Financial Group restated a “hold” rating and issued a $1.60 price objective (down from $2.00) on shares of OPKO Health in a research note on Thursday, October 30th. JPMorgan Chase & Co. began coverage on shares of OPKO Health in a report on Thursday, November 20th. They set a “neutral” rating for the company. Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a report on Thursday, October 30th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $2.28.

OPKO Health Trading Down 2.9%

The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.32 and a current ratio of 3.70. The company’s 50 day moving average is $1.32 and its 200 day moving average is $1.37. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -5.28 and a beta of 1.39.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.05. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.67%. The company had revenue of $151.67 million for the quarter, compared to the consensus estimate of $165.74 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The business’s revenue was down 12.6% compared to the same quarter last year. On average, research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Insider Activity at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 580,000 shares of the firm’s stock in a transaction dated Friday, November 21st. The shares were bought at an average price of $1.33 per share, with a total value of $771,400.00. Following the acquisition, the chief executive officer owned 216,706,448 shares of the company’s stock, valued at $288,219,575.84. This trade represents a 0.27% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders purchased 1,843,300 shares of company stock valued at $2,421,491. 49.69% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of OPK. Caprock Group LLC bought a new stake in OPKO Health in the 3rd quarter valued at $26,000. Swiss Life Asset Management Ltd acquired a new stake in shares of OPKO Health during the 3rd quarter valued at about $30,000. Savant Capital LLC acquired a new stake in shares of OPKO Health during the 3rd quarter valued at about $33,000. Arrow Financial Corp bought a new stake in OPKO Health in the third quarter valued at about $39,000. Finally, Fisher Asset Management LLC acquired a new position in OPKO Health in the second quarter worth about $40,000. 64.63% of the stock is owned by institutional investors.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.